FDA Approves High-Dose Spinraza for SMA Patients

For families living with spinal muscular atrophy, a new treatment breakthrough just arrived with FDA approval of a high-dose Spinraza regimen that shows better motor function and survival outcomes.

The newly approved dosing option features two 50 mg loading doses given two weeks apart, followed by 28 mg maintenance doses every four months. This replaces the original regimen that required four loading doses over six weeks and 12 mg maintenance doses.

Both new patients and those already taking Spinraza can access the high-dose treatment, which will be available in U.S. clinics within weeks. Patients currently on the original regimen can switch with just one 50 mg loading dose.

The approval comes after more than 10 years of clinical data on Spinraza, the first therapy ever proven to slow SMA progression. Spinal muscular atrophy is a genetic disorder that causes motor neurons to die, leading to progressive muscle weakness and loss of movement.

Clinical trials showed previously untreated children with SMA who received the high-dose regimen had better outcomes than those on the original dose. Patients who switched from the standard regimen to the higher dose generally maintained stable motor function or saw improvements.

The Ripple Effect

This approval follows similar decisions in the European Union, Switzerland, and Japan, with Biogen now working to bring the option to patients worldwide. The SMA community celebrated the news with enthusiasm after years of advocacy and participation in clinical trials.

"Today's approval of High Dose Spinraza makes progress in addressing unmet needs of the SMA community," said Kenneth Hobby, president of Cure SMA. Nearly a decade after Spinraza changed what families thought was possible, this advancement offers renewed hope.

Dr. Richard Finkel, director of the Center for Experimental Neurotherapics at St. Jude Children's Research Hospital, believes the high-dose regimen will play an important role in the future of SMA care. The safety profile remained consistent with lower doses, with the most common side effects being infections that are manageable with proper medical care.

This milestone represents years of commitment from researchers, families, and the SMA community working together to optimize treatment options for a disease that once had no therapies at all.